Alaunos Therapeutics, Inc. — Investor Relations & Filings

Alaunos Therapeutics, Inc. is a clinical-stage cellular immuno-oncology company developing T-cell receptor (TCR)-T cell therapies for the treatment of solid tumors. The company's approach targets cancer-specific neoantigens that arise from genomic hotspot mutations. It utilizes its proprietary hunTR® (human neoantigen T cell Receptor) platform as a discovery engine to identify and expand its library of tumor-specific TCRs. For manufacturing its cell therapies, Alaunos employs the *Sleeping Beauty* non-viral gene transfer system, a technology noted for its favorable safety profile and rapid, cost-effective production. The company's mission is to deliver tumor-specific T-cell therapies to cancer patient populations with unmet clinical needs.